化合物JCN037 T8431

Product Introduction
Bioactivity


英文名: JCN037

描述: JCN037 是能透过血脑屏障的EGFR 共价抑制剂，对 EGFR、p-wtEGFR 和 pEGFRvⅢ 的IC50值分别为 2.49、3.95 和4.48 nM。

体内活性: Relative to the conventional EGFR TKIs erlotinib and lapatinib, JCN037 displayed potent activity against EGFR amplified/mutant patient-derived cell cultures, significant BBB penetration (2:1 brain-to-plasma ratio), and superior efficacy in an EGFR-driven orthotopic glioblastoma xenograft model.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 10 mg/mL (26.58 mM)


关键字: Epidermal growth factor receptor | JCN037 | HER1 | Inhibitor | inhibit | EGFR | JCN 037 | JGK-037 | ErbB-1 | JGK037 | JGK 037 | JCN-037

相关产品: Tyrosine kinase-IN-7 | EGFR-IN-99 | (±)-Norcantharidin | Tyrphostin AG 112 | BKI-1369 | Rilematovir | PD173074 | ZD-4190 | NSC 228155 | AG-1557 hydrochloride (189290-58-2(free base))

相关库: Membrane Protein-targeted Compound Library | Anti-Lung Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Colorectal Cancer Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Pancreatic Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library

化合物JCN037 T8431信息由TargetMol中国为您提供，如您想了解更多关于化合物JCN037 T8431报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途